Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 29;42(8):112927.
doi: 10.1016/j.celrep.2023.112927. Epub 2023 Aug 1.

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype

Affiliations
Free article

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype

Estefania Cuesta-Borràs et al. Cell Rep. .
Free article

Abstract

Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to bypass therapy-induced cell death. Through combining functional pulse-chase experiments in engineered cells and transcriptomic analyses, we identify DPPA3 as a master regulator of slow-cycling and chemoresistant phenotype in colorectal cancer (CRC). We find a vicious DPPA3-HIF1α feedback loop that downregulates FOXM1 expression via DNA methylation, thereby delaying cell-cycle progression. Moreover, downregulation of HIF1α partially restores a chemosensitive proliferative phenotype in DPPA3-overexpressing cancer cells. In cohorts of CRC patient samples, DPPA3 overexpression acts as a predictive biomarker of chemotherapeutic resistance that subsequently requires reduction in its expression to allow metastatic outgrowth. Our work demonstrates that slow-cycling cancer cells exploit a DPPA3/HIF1α axis to support tumor persistence under therapeutic stress and provides insights on the molecular regulation of disease progression.

Keywords: 3D organoids; CP: Cancer; DNA methylation; FOXM1; cancer persistence; drug-tolerant persister cancer cell; hypoxia; recurrence; relapse; slow-cycling cancer cell; therapy resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests I.C., L.R., L.C., J.M.-Q., and H.G.P. report receiving commercial research grants from Blueprint medicines, Cyclacel, Grifols, Ikena Oncology, and Novartis. A.G.-A. declares speakers’ bureau for Angelini and travel, accommodations, and expenses from Pfizer, Ipsen, and Eisai. J.H. reports receiving honoraria from speakers’ bureaus from Adacap, Angelini, Bayer, Eisai, Ipsen, Leo Pharma, Novartis, and Roche. E.E. discloses personal financial interests receiving honoraria for advisory roles, travel grants, and research grants from Amgen, Bayer, Hoffman-La Roche, Merck Serono, Sanofi, Pierre Fabre, MSD, Organon, Novartis, and Servier. J.T. reports personal financial interests in the form of a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiff Oncology, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Tessa Therapeutics, TheraMyc, and Tolremo Therapeutics; stocks of Oniria Therapeutics; and also educational collaboration with Imedex/HMP, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER). P.N. discloses personal financial interests of receiving honoraria or consultation fees from Novartis, Bayer, and MSD Oncology and receiving travel and accommodations paid or reimbursed by Novartis. J.C. declares receiving honoraria for serving on speakers’ bureaus and scientific advisory from Advanced Accelerator Applications (AAA), Amgen, Bayer, Eisai, Exelixis, Ipsen, Lilly, Merck Serono, Novartis, Pfizer, and Sanofi and receiving research grants from AAA, AstraZeneca, Bayer, Eisai, Novartis, and Pfizer. H.G.P. is a scientific co-founder, Chief Scientific Officer (CSO), executive board member, and equity owner of Oniria Therapeutics; he does not receive financial compensation as a CSO. I.P. is a scientific co-founder, scientific advisory board member, and equity owner of Oniria Therapeutics; she does not receive financial compensation as a consultant.

LinkOut - more resources